Frequently Asked Questions: LuciNiro (nirogacestat)

Frequently Asked Questions: LuciNiro (nirogacestat)

Q1: What is the usual dosage of LuciNiro?

A: The standard dose is 150 mg twice daily, totaling 300 mg per day. Each dose includes three 50 mg tablets, taken together around 12 hours apart. Tablets should be swallowed whole and can be taken with or without food.

Q2: How long does it take to see results?

A: In clinical trials, the average time to visible tumor shrinkage was about 5.6 months. However, many patients noticed improvements in pain, mobility, or daily comfort much sooner, even before the tumor visibly shrank.

Q3: What side effects should I expect?

A: Most side effects are mild to moderate and manageable. The most common include:

• Diarrhea
• Nausea
• Fatigue
• Rash
• Low phosphate levels
• Menstrual changes in premenopausal women

More serious side effects are rare but should be monitored. Regular lab tests help detect and manage these early.

Q4: Can children take LuciNiro?

A: Currently, LuciNiro is approved only for adults with progressing desmoid tumors. Its use in children or teens is still being studied.

Q5: What if I miss a dose?

A: If you miss a dose or vomit after taking LuciNiro, do not take a double dose. Just continue with your next scheduled dose. Speak to your doctor if this happens often.

Q6: Is LuciNiro safe during pregnancy or breastfeeding?

A: No. LuciNiro is not recommended during pregnancy or while breastfeeding due to potential risks. Women of childbearing age should use effective contraception during treatment and for a period afterward.

Q7: How is LuciNiro different from chemotherapy or surgery?

A: LuciNiro is a targeted therapy, not traditional chemotherapy. It blocks a specific protein (γ-secretase) that helps desmoid tumors grow.

• It’s taken orally at home, not through an IV.
• It’s often used when surgery is risky, tumors recur, or long-term control is needed.

The Science Behind LuciNiro

The DeFi Clinical Trial: A Landmark Study

Study Name: DeFi (NCT03785964)
Type: Phase 3, double-blind, placebo-controlled
Participants: 142 adults with progressing desmoid tumors
Treatment: 150 mg LuciNiro orally twice daily, in 28-day cycles
Goals:

• Primary Endpoint: Progression-Free Survival (PFS)
• Secondary Endpoints: Tumor response, symptom relief, pain control, and quality of life

What the Trial Found:

1. Tumor Control:

• Patients taking LuciNiro had a 71% lower risk of tumor growth or death compared to placebo (HR: 0.29).
• Nearly 41% of patients saw tumor shrinkage, vs. 8% in the placebo group.

2. Symptom Relief:

• Patients reported less pain, improved daily functioning, and better overall quality of life.

3. Side Effects:
Most were manageable and included:

• Diarrhea (84%)
• Nausea (54%)
• Fatigue (51%)
• Low phosphate levels (42%)
• Rash (32%)

4. Reproductive Health:

• About 75% of women of childbearing age experienced ovarian dysfunction (e.g., missed periods).
• In many cases, these changes were reversible after stopping treatment or over time.

Who Benefited?

LuciNiro was effective across a wide range of patients:

• Tumors of all sizes
• Different age groups
• Patients with or without pain
• Different genetic subtypes (e.g., CTNNB1 mutations)

Regulatory Approvals:

• United States: FDA approved LuciNiro in November 2023 (brand name: Ogsiveo)
• European Union: Approved in 2025, expanding patient access across Europe

Looking Ahead: LuciNiro Beyond Desmoid Tumors

While LuciNiro is currently used for desmoid tumors, research is ongoing in areas like:

• Multiple myeloma (in combination with BCMA-targeted therapies)
• Pediatric desmoid tumors
• Other solid tumors (early-stage trials)

True or False? LuciNiro Quick Facts